The CHF16m ($19m) funding round raised by medical device company MyoPowers takes its total capital gathered to about $24m.

The corporate venturing unit of Switzerland-based healthcare company Novartis has reinvested in local medical device maker MyoPowers’ CHF16m ($19m) round.

Venture capital firm Truffle Capital is leading MyoPowers’ series B round, which also includes new investors BlueOcean Ventures and two unnamed private investors. All investors in the company’s $5m series A round last year, including Novartis, investment firm Gran Plasa and venture firm Initiative Capital Romandie, joined the latest round, which means the company has now raised about $24m.

…